LONDON, May 12, 2017 /PRNewswire/ --
Hybrigenics' main focus is the development of inecalcitol as a niche treatmentfor leukaemia. In February it presented encouraging initial results for inecalcitol in combination with oral imatinib in chronic myeloid leukaemia (CML), with 43% of patients responding in a Phase II study that will complete in H218. A Phase II trial
(Logo: http://photos.prnewswire.com/prnh/20130417/608168 )
Our DCF valuation is €141m or €3.9 per share, from €146m or €4.1 per share. The key change to our numbers relates to inecalcitol in CML, where we have increased the probability of success to 40% from 30% due to positive interim data; and to CLL, where we have reduced the probability of success to 20% from 30% as we await guidance on the development path. We have also updated our model for the FY16 net cash position of €8.5m.
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information please contact:
Juan Pedro Serrate Edison Investment Research +44(0)20-3681-2534
Lala Gregorek Edison Investment Research +44(0)20-3681-2297 email@example.com
Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:
SOURCE Edison Investment Research
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All